PL4000615T3 - Podwójne antagonisty tnfr1 i agonisty tnfr2 do stosowania w chorobach nerek - Google Patents
Podwójne antagonisty tnfr1 i agonisty tnfr2 do stosowania w chorobach nerekInfo
- Publication number
- PL4000615T3 PL4000615T3 PL20207534.7T PL20207534T PL4000615T3 PL 4000615 T3 PL4000615 T3 PL 4000615T3 PL 20207534 T PL20207534 T PL 20207534T PL 4000615 T3 PL4000615 T3 PL 4000615T3
- Authority
- PL
- Poland
- Prior art keywords
- dual
- renal diseases
- tnfr2 agonists
- tnfr1 antagonists
- tnfr1
- Prior art date
Links
- 101100425758 Mus musculus Tnfrsf1b gene Proteins 0.000 title 1
- 101150009046 Tnfrsf1a gene Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 230000009977 dual effect Effects 0.000 title 1
- 208000017169 kidney disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20207534.7A EP4000615B1 (en) | 2020-11-13 | 2020-11-13 | Dual tnfr1 antagonists and tnfr2 agonists for use in renal diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4000615T3 true PL4000615T3 (pl) | 2022-12-19 |
Family
ID=73448924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20207534.7T PL4000615T3 (pl) | 2020-11-13 | 2020-11-13 | Podwójne antagonisty tnfr1 i agonisty tnfr2 do stosowania w chorobach nerek |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230414562A1 (pl) |
| EP (1) | EP4000615B1 (pl) |
| JP (1) | JP7462116B2 (pl) |
| CN (1) | CN116568296A (pl) |
| AU (1) | AU2021378077B2 (pl) |
| CA (1) | CA3197986A1 (pl) |
| ES (1) | ES2930093T3 (pl) |
| PL (1) | PL4000615T3 (pl) |
| WO (1) | WO2022101389A1 (pl) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2363127A1 (en) | 2006-01-18 | 2011-09-07 | Evolva SA | PPAR Modulators |
| EP2150111B1 (en) * | 2007-01-18 | 2016-10-19 | Evolva SA | Substituted 1,3-dioxanes useful as ppar modulators |
| US20120142766A1 (en) | 2007-11-21 | 2012-06-07 | Evolva Sa | Substituted 1,3-dioxanes and their uses |
| US20160193179A1 (en) | 2012-12-18 | 2016-07-07 | Kjell Steinar Sakariassen | Treatment of Cardiovascular Risk in Diabetic Patients |
-
2020
- 2020-11-13 PL PL20207534.7T patent/PL4000615T3/pl unknown
- 2020-11-13 EP EP20207534.7A patent/EP4000615B1/en active Active
- 2020-11-13 ES ES20207534T patent/ES2930093T3/es active Active
-
2021
- 2021-11-12 CN CN202180074898.5A patent/CN116568296A/zh active Pending
- 2021-11-12 JP JP2023528450A patent/JP7462116B2/ja active Active
- 2021-11-12 US US18/252,339 patent/US20230414562A1/en active Pending
- 2021-11-12 WO PCT/EP2021/081482 patent/WO2022101389A1/en active Application Filing
- 2021-11-12 CA CA3197986A patent/CA3197986A1/en active Pending
- 2021-11-12 AU AU2021378077A patent/AU2021378077B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021378077B2 (en) | 2024-03-14 |
| EP4000615B1 (en) | 2022-10-19 |
| US20230414562A1 (en) | 2023-12-28 |
| JP2023554588A (ja) | 2023-12-28 |
| EP4000615A1 (en) | 2022-05-25 |
| CN116568296A (zh) | 2023-08-08 |
| AU2021378077A1 (en) | 2023-05-25 |
| WO2022101389A1 (en) | 2022-05-19 |
| CA3197986A1 (en) | 2022-05-19 |
| ES2930093T3 (es) | 2022-12-07 |
| JP7462116B2 (ja) | 2024-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL200572A0 (en) | Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases | |
| IL198829A0 (en) | Gm-csf antagonist use in treating chronic inflammatory diseases | |
| MX2011012691A (es) | Combinacion de un antagonista de tnf-alfa y un antagonista de vegf para utilizarse en el tratamiento o en la prevencion de enfermedades de los ojos. | |
| CL2013002869A1 (es) | Una combinacion que contiene 2-amino-n-[7-metoxi-8-(3-morfolin-4-ilpropoxi)-2,3-dihidroimidazo[1,2-c]quinazolin-5-il]pirimidin-5-carboxamida y abt-737; y su uso para el tratamiento o profilaxis de cancer de mama, en particular cáncer de mama inflamatorio, cancer de mama triple negativo, cancer de mama positivo a receptor de her2 y cancer de mama positivo a receptor de hormona. | |
| AR107303A1 (es) | Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit | |
| IL279015A (en) | Anti-interleukin-17A antibody, its pharmaceutical preparation and its use | |
| IL199045A0 (en) | Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases | |
| ZA202206885B (en) | Anti-pd-1-anti-vegfa bispecific antibody, pharmaceutical composition and use thereof | |
| IL291034A (en) | Radiolabeling methods for grpr antagonists and their kits | |
| SG11201911599XA (en) | Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss | |
| SG10202006451QA (en) | Managing transactions in multiple blockchain networks | |
| HK1215540A1 (zh) | 用於治療或預防疾病的因子 蛋白、因子 蛋白及其抑制劑 | |
| IL274836A (en) | Dosing plan of vidofludimus for use in the prevention or treatment of chronic inflammatory diseases and/or autoimmune diseases | |
| HK1224184A1 (zh) | 用於治療炎性疾病的化合物、藥物組合物和方法 | |
| SG11202103021VA (en) | Cd40l antagonist and uses thereof | |
| EP3749295A4 (en) | FIBROBLAST BINDING AGENTS AND USES THEREOF | |
| IL277634A (en) | Leptin receptor agonist antibody for use in the treatment of metabolic dysfunction or hypoleptinemia | |
| PL3970344T3 (pl) | Zarządzanie buforem w systemach dostarczania zawartości | |
| SG11202010521VA (en) | Use of neutrophil elastase inhibitors in liver disease | |
| IL289354A (en) | Anti-154cd antibodies and their uses | |
| EP4034132A4 (en) | ERK5 DEGRADER AS THERAPEUTIC FOR CANCER AND INFLAMMATORY DISEASES | |
| DOP2016000003A (es) | Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán | |
| PL4000615T3 (pl) | Podwójne antagonisty tnfr1 i agonisty tnfr2 do stosowania w chorobach nerek | |
| EP3617224A4 (en) | SN 10 SELECTIVE ANTAGONIST OF TNFR1 AND ITS USE TO TREAT INFLAMMATORY DISEASE OF THE INTESTINE | |
| IL284981A (en) | Antagonists to semaphorin-4d for use in cancer therapy |